Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis-Reference-Cited by-同舟云学术

Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis

Published:2024-01-09 Issue:3 Volume:41 Page:1046-1061
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Paller Amy S.,Pinter Andreas,Wine Lee Lara,Aschoff Roland,Zdybski Jacek,Schnopp Christina,Praestgaard Amy,Bansal Ashish,Shumel Brad,Prescilla Randy,Bastian Mike^ORCID

Funder

Sanofi

Regeneron Pharmaceuticals

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12325-023-02753-1.pdf

Reference26 articles.

1. Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract. 2006;60:984–92. https://doi.org/10.1111/j.1742-1241.2006.01047.x.

2. Chamlin SL, Chren MM. Quality-of-life outcomes and measurement in childhood atopic dermatitis. Immunol Allergy Clin North Am. 2010;30:281–8. https://doi.org/10.1016/j.iac.2010.05.004.

3. Barbarot S, Silverberg JI, Gadkari A, et al. The family impact of atopic dermatitis in the pediatric population: results from an international cross-sectional study. J Pediatr. 2022;246:220-226.e5. https://doi.org/10.1016/j.jpeds.2022.04.027.

4. Ben-Gashir MA, Seed PT, Hay RJ. Quality of life and disease severity are correlated in children with atopic dermatitis. Br J Dermatol. 2004;150:284–90. https://doi.org/10.1111/j.1365-2133.2004.05776.x.

5. El Achkar Mello ME, Simoni AG, Rupp ML, et al. Quality of life of pediatric patients with atopic dermatitis and their caregivers. Arch Dermatol Res. 2023. https://doi.org/10.1007/s00403-023-02544-2.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Atopic diseases—Diagnostics, mechanisms, and exposures;Pediatric Allergy and Immunology;2024-07

2. An updated reappraisal of dupilumab in children and adolescents with moderate–severe atopic dermatitis;Pediatric Allergy and Immunology;2024-06

3. Correction to: Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis;Advances in Therapy;2024-05-02